Literature DB >> 16125481

Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy.

Kunihiro Kinjo1, Hiroshi Sato, Yasuhiko Sakata, Daisaku Nakatani, Hiroya Mizuno, Masahiko Shimizu, Masami Nishino, Hiroshi Ito, Jun Tanouchi, Shinsuke Nanto, Masatsugu Hori.   

Abstract

We evaluated the interaction between inflammation and survival benefit from statin therapy in patients who had acute myocardial infarction. Although 1-year mortality did not differ between patients who used statin therapy and those who did not, among patients who had C-reactive protein (CRP) concentrations in the lower 2 tertiles (<2.9 mg/L), 1-year mortality was higher in patients who used statin therapy than in those who did not within the highest CRP-defined tertile (> or =2.9 mg/L). Statin therapy significantly decreased the hazard ratio for 1-year mortality in patients who had high CRP levels to approximately the hazard present for patients who had low CRP levels and did not receive statin therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16125481     DOI: 10.1016/j.amjcard.2005.04.030

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Enhanced spontaneous thrombolysis: a new therapeutic challenge.

Authors:  I B Kovacs; D A Gorog; J Yamamoto
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

2.  Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results.

Authors:  Subodh Verma; Eva M Lonn; Alykhan Nanji; Kevin Browne; Richard Ward; Annette Robertson; Heather Conradson; Kathy Hildebrand; Rollin Brant; Todd J Anderson
Journal:  Can J Cardiol       Date:  2009-07       Impact factor: 5.223

3.  A Simple Risk Stratification Model for ST-Elevation Myocardial Infarction (STEMI) from the Combination of Blood Examination Variables: Acute Myocardial Infarction-Kyoto Multi-Center Risk Study Group.

Authors:  Kenji Yanishi; Takeshi Nakamura; Naohiko Nakanishi; Isao Yokota; Kan Zen; Tetsuhiro Yamano; Hirokazu Shiraishi; Takeshi Shirayama; Jun Shiraishi; Takahisa Sawada; Yoshio Kohno; Makoto Kitamura; Keizo Furukawa; Satoaki Matoba
Journal:  PLoS One       Date:  2016-11-11       Impact factor: 3.240

4.  Beneficial effect of polaprezinc on cardiac function post-myocardial infarction: A prospective and randomized clinical trial.

Authors:  Fumitsugu Yoshikawa; Tetsu Nakajima; Masaharu Hanada; Kazuo Hirata; Tohru Masuyama; Ryuichi Aikawa
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

5.  Particulate air pollution, progression, and survival after myocardial infarction.

Authors:  Antonella Zanobetti; Joel Schwartz
Journal:  Environ Health Perspect       Date:  2007-02-20       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.